Keytruda 100 MG/4 ML vial 4ML
Ended Awarded
- Contract number
- SPE2DB25FX1XC
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $81,896
Award facts
- Contract value 100% obligated
- $81,895.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $81,895.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. This firm fixed-price delivery order, issued on June 2, 2025, with an ultimate completion date of June 24, 2025, represents a specific procurement executed under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The SPE2DB program IDC, valued at $499.999 billion and valid through November 2026, enables the Defense Logistics Agency to issue multiple delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs across Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its woman-owned small business designation to compete effectively for Defense Logistics Agency contracts without set-aside designations. The company's extensive portfolio includes branded and generic prescription drugs, biologics, over-the-counter medications, and specialty pharmaceuticals such as oncology treatments and auto-injectors. Keytruda, an immunotherapy medication used in cancer treatment, aligns with the company's track record of supplying specialized pharmaceutical products directly to Department of Defense healthcare sites nationwide, reinforcing its role as a key distributor of critical medications to military health facilities.
Quick answers
Who was awarded contract SPE2DB25FX1XC?
SPE2DB25FX1XC was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on June 2, 2025.
How much is contract SPE2DB25FX1XC worth?
The government has obligated $81,896 on SPE2DB25FX1XC.
Is contract SPE2DB25FX1XC an order under another contract?
Yes. SPE2DB25FX1XC is a delivery order under SPE2DB22D9353, an indefinite delivery contract.
Was contract SPE2DB25FX1XC competed?
The extent of competition for SPE2DB25FX1XC was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award